Pay in 4 interest-free payments of $7.01 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
R., & Lpez-Otn, C
The Clinical Data: Everything Published So Far Phase 1 First-in-Human (Oral Formulation) Published: The Lancet, June 2025 Participants: 144 adults with overweight or obesity (BMI 25.039.9), no diabetes Duration: Up to 12 weeks Dosing: Once-daily oral amycretin, up to 2 50 mg Results: - 50 mg dose: 10.4% mean body weight change - 2 50 mg dose: 13.1% mean body weight change - Placebo: 1.2% 13% weight loss in 12 weeks
Patients can benefit from this peptide through tailored treatment plans aligning with their health and weight objectives
Consent to receive marketing text messages is not a condition of purchase
US$ 25.51
US$ 22.44
US$ 22.83
US$ 26.64
US$ 25.82
US$ 29.75
US$ 28.02
